Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE60.5000
- TODAY'S CHANGE (%)1.4400 (2.4382%)
- Bid / Lots60.4900/ 2
- Ask / Lots60.6200/ 8
- Open / Previous Close60.4200 / 59.0600
- Day Range
- 52 Week Range
- Volume626,992
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 12224 | 60.24 |
| 09:33 ET | 7006 | 60.405 |
| 09:35 ET | 13294 | 61.34 |
| 09:37 ET | 2740 | 60.605 |
| 09:39 ET | 7094 | 61.11 |
| 09:42 ET | 3403 | 61.29 |
| 09:44 ET | 13209 | 61.15 |
| 09:46 ET | 2000 | 60.86 |
| 09:48 ET | 1200 | 60.2 |
| 09:50 ET | 8981 | 60.08 |
| 09:51 ET | 1800 | 60.05 |
| 09:53 ET | 9205 | 60.11 |
| 09:55 ET | 9600 | 59.91 |
| 09:57 ET | 2581 | 59.9 |
| 10:00 ET | 1200 | 59.88 |
| 10:02 ET | 8995 | 60.1 |
| 10:04 ET | 13663 | 59.505 |
| 10:06 ET | 200 | 59.45 |
| 10:08 ET | 2955 | 59.475 |
| 10:09 ET | 8363 | 60.07 |
| 10:11 ET | 1500 | 60.28 |
| 10:13 ET | 700 | 60.02 |
| 10:15 ET | 37423 | 60.285 |
| 10:18 ET | 4384 | 60.32 |
| 10:20 ET | 3933 | 60.62 |
| 10:22 ET | 1200 | 60.985 |
| 10:24 ET | 1901 | 60.88 |
| 10:26 ET | 1308 | 61.0433 |
| 10:27 ET | 9169 | 61.92 |
| 10:29 ET | 10200 | 61.8 |
| 10:31 ET | 8183 | 62.1 |
| 10:33 ET | 8138 | 61.85 |
| 10:36 ET | 6417 | 61.7 |
| 10:38 ET | 1137 | 61.435 |
| 10:40 ET | 3415 | 61.775 |
| 10:42 ET | 1300 | 61.87 |
| 10:44 ET | 3200 | 61.85 |
| 10:45 ET | 7722 | 62.06 |
| 10:47 ET | 8620 | 62.405 |
| 10:49 ET | 8800 | 62.43 |
| 10:51 ET | 3100 | 62.32 |
| 10:54 ET | 2971 | 62.47 |
| 10:56 ET | 4564 | 62.2 |
| 10:58 ET | 3088 | 61.835 |
| 11:00 ET | 4790 | 62.16 |
| 11:02 ET | 4500 | 61.97 |
| 11:03 ET | 1493 | 62.005 |
| 11:05 ET | 1890 | 62.005 |
| 11:07 ET | 4446 | 61.88 |
| 11:09 ET | 1894 | 61.96 |
| 11:12 ET | 1435 | 62 |
| 11:14 ET | 3069 | 62.1 |
| 11:16 ET | 750 | 62 |
| 11:18 ET | 6665 | 62.075 |
| 11:20 ET | 2358 | 61.775 |
| 11:21 ET | 2835 | 61.745 |
| 11:23 ET | 2088 | 61.59 |
| 11:25 ET | 31519 | 60.885 |
| 11:27 ET | 1900 | 60.67 |
| 11:30 ET | 300 | 60.71 |
| 11:32 ET | 6280 | 61.19 |
| 11:34 ET | 1100 | 61.33 |
| 11:36 ET | 1400 | 61.375 |
| 11:38 ET | 2605 | 61.8704 |
| 11:39 ET | 1139 | 61.89 |
| 11:41 ET | 1140 | 61.799 |
| 11:43 ET | 3236 | 61.841 |
| 11:45 ET | 2392 | 61.815 |
| 11:48 ET | 1739 | 61.61 |
| 11:50 ET | 958 | 61.585 |
| 11:52 ET | 3927 | 61.23 |
| 11:54 ET | 1606 | 61.095 |
| 11:56 ET | 1906 | 60.98 |
| 11:57 ET | 244 | 60.81 |
| 11:59 ET | 600 | 60.81 |
| 12:01 ET | 1756 | 60.56 |
| 12:03 ET | 3879 | 60.78 |
| 12:06 ET | 3270 | 60.715 |
| 12:08 ET | 2028 | 60.805 |
| 12:10 ET | 3442 | 60.75 |
| 12:12 ET | 1750 | 60.795 |
| 12:14 ET | 1251 | 60.775 |
| 12:15 ET | 8108 | 61.15 |
| 12:17 ET | 3123 | 61.18 |
| 12:19 ET | 1500 | 61.23 |
| 12:21 ET | 1100 | 61.31 |
| 12:24 ET | 3121 | 61.06 |
| 12:26 ET | 791 | 60.86 |
| 12:28 ET | 530 | 60.71 |
| 12:30 ET | 200 | 60.72 |
| 12:32 ET | 4400 | 60.89 |
| 12:33 ET | 2466 | 60.945 |
| 12:35 ET | 4605 | 61.28 |
| 12:39 ET | 800 | 61.11 |
| 12:42 ET | 1665 | 61.03 |
| 12:44 ET | 100 | 60.96 |
| 12:46 ET | 3500 | 61.025 |
| 12:48 ET | 200 | 61.115 |
| 12:50 ET | 380 | 61.0675 |
| 12:51 ET | 800 | 61.15 |
| 12:53 ET | 2526 | 61.185 |
| 12:55 ET | 817 | 61.09 |
| 12:57 ET | 880 | 61.09 |
| 01:00 ET | 608 | 60.98 |
| 01:02 ET | 800 | 60.77 |
| 01:04 ET | 300 | 60.855 |
| 01:06 ET | 100 | 60.72 |
| 01:08 ET | 1613 | 60.38 |
| 01:09 ET | 500 | 60.565 |
| 01:11 ET | 6605 | 60.86 |
| 01:13 ET | 707 | 60.63 |
| 01:15 ET | 200 | 60.72 |
| 01:18 ET | 100 | 60.74 |
| 01:20 ET | 1200 | 60.7 |
| 01:22 ET | 620 | 60.5 |
| 01:24 ET | 531 | 60.43 |
| 01:26 ET | 1769 | 60.46 |
| 01:27 ET | 1311 | 60.48 |
| 01:29 ET | 100 | 60.54 |
| 01:31 ET | 1383 | 60.56 |
| 01:36 ET | 4677 | 60.5 |
| 01:38 ET | 500 | 60.44 |
| 01:40 ET | 813 | 60.37 |
| 01:42 ET | 888 | 60.57 |
| 01:44 ET | 691 | 60.32 |
| 01:45 ET | 900 | 60.41 |
| 01:47 ET | 100 | 60.33 |
| 01:49 ET | 1054 | 60.435 |
| 01:51 ET | 1628 | 60.3475 |
| 01:54 ET | 200 | 60.35 |
| 01:56 ET | 1200 | 60.58 |
| 01:58 ET | 311 | 60.64 |
| 02:00 ET | 159 | 60.59 |
| 02:02 ET | 800 | 60.57 |
| 02:03 ET | 100 | 60.5 |
Nov 5, 2024
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition, from 9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 1, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones
12:43PM ET on Friday Nov 01, 2024 by Dow JonesDJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones
10:30AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
*DJ Agios Pharmaceuticals 3Q EPS $16.22 >AGIO, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow JonesAgios Reports Business Highlights and Third Quarter 2024 Financial Results, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 3.4B | 4.9x | --- |
Xenon Pharmaceuticals Inc | 3.4B | -16.1x | --- |
Edgewise Therapeutics Inc | 3.4B | -23.3x | --- |
MoonLake Immunotherapeutics | 3.3B | -41.4x | --- |
Iovance Biotherapeutics Inc | 3.2B | -7.2x | --- |
Apogee Therapeutics Inc | 3.6B | -27.0x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
|---|---|
Revenue (TTM) | $32.9M |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $12.28 |
Book Value | $14.50 |
P/E Ratio | 4.9x |
Price/Sales (TTM) | 102.5 |
Price/Cash Flow (TTM) | 4.6x |
Operating Margin | 2,075.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
